Yanyan Fan

Yanyan Fan

Auto-generated profile, based on publicly available information

Yanyan Fan

National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YZYulin Zhang
Yulin Zhang
YLYi Li
Yi Li
JZJi Zeng
Ji Zeng
YCYanzi Chang
Yanzi Chang
SHShouhua Han
Shouhua Han
BCBin Cao
Bin Cao
Purpose: Pseudomonas aeruginosa bacteremia presents a severe challenge to hospitalized patients. However, to date, the risk factors for mortality among inpatients with P. aeruginosa bacteremia in China remain unclear. Patients and Methods: This retrospective multicenter study was performed to analyze 215 patients with culture-confirmed P. aeruginosa bacteremia in five healthcare centers in China during the years 2012– 2019. Results: Of 215 patients with P. aeruginosa bacteremia, 61 (28.4%) died during the study period. Logistic multivariable analysis revealed that cardiovascular disease (OR=3.978, P=0.001), blood transfusion (OR=5.855, P< 0.001) and carbapenem-resistant P. aeruginosa (CRPA) phenotype (OR=4.485, P=0.038) constituted the independent risk factors of mortality. Furthermore, both CRPA and multidrug-resistant P. aeruginosa (MDRPA) phenotypes were found to be significantly associated with 5-day mortality (Log-rank, P< 0.05). Conclusion: This study revealed a high mortality rate amongst hospitalized patients with P. aeruginosa bacteremia, and those with cardiovascular diseases, CRPA and MDRPA phenotypes, should be highlighted and given appropriate management in China.

1 May 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
HLHaibo Li
Haibo Li
ZLZiyao Li
Ziyao Li
XCXiaojing Cui
Xiaojing Cui
XLXinmeng Liu
Xinmeng Liu
JZJiankang Zhao
Jiankang Zhao
BCBin Cao
Bin Cao
Purpose: Mycobacterium tuberculosis (MTB) infection poses a significant global health challenge, with conventional diagnostic methods like acid-fast smear and culture techniques exhibiting limitations in sensitivity and efficiency. This retrospective study examined 4098 clinical samples from China-Japan Friendship Hospital between March 2018 and March 2019, focusing on the diagnostic performance of GeneXpert MTB/RIF across different specimen types. Methods: The study encompassed various sample types, including bronchoalveolar lavage fluid (BALF), sputum, lung tissues, hydrothorax, and others. All samples were performed via acid-fast-straining, GeneXpert MTB/RIF and culture. Results: GeneXpert MTB/RIF demonstrated superior sensitivity (81.46%) and specificity (98.98%) in respiratory specimens compared to tissues (62.50%) and hydrothorax (46.15%). Notably, in acid-fast-straining-negative samples, GeneXpert MTB/RIF showed sensitivity and specificity of 73.43% and 98.8%, respectively, and reduced false negatives of acid-fast staining. Furthermore, the study explored Cycler Threshold (CT) values, revealing associations with bacterial load and sample types. Conclusion: The findings highlight the importance of considering sample types in MTB diagnosis and underscore the potential of GeneXpert MTB/RIF as a valuable diagnostic tool, especially in respiratory specimens, contributing to improved tuberculosis management strategies. Additionally, the study recommended direct GeneXpert MTB/RIF testing of hydrothorax samples instead of acid-fast staining, further enhancing diagnostic accuracy and efficiency.

20 January 2023 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
LMLiang Ma
Liang Ma
YFYanyan Fan
Yanyan Fan
XKXiaomu Kong
Xiaomu Kong
YJYongwei Jiang
Yongwei Jiang
HHHong Huang
Hong Huang
YCYongtong Cao
Yongtong Cao
Objectives. To establish and evaluate the analytical and clinical performance of the Flash20 SARS-CoV-2 nucleic acid rapid detection system free of RNA extraction. Methods. The limit of detection (LoD) was determined using a negative nasopharyngeal swab matrix spiked with different concentrations of SARS-CoV-2 virus; a total of 734,337 reference sequences of viral genomes from GenBank were used for the in-silico analysis to assess the inclusivity of the assay. The specificity of the system was evaluated by testing 27 medically relevant organisms. A total of 115 clinical specimens were collected and tested on the Flash20 SARS-CoV-2 detection system and with an FDA-approved comparator test to assess the clinical performance of the system. Results. The LoD of the Flash20 SARS-CoV-2 detection system is 250 copies/mL with a positive rate 90 (n=20); alignments results showed that over 99 identity of the primer and probe of the Flash20 SARS-CoV-2 nucleic acid rapid detection system to the available SARS-CoV-2 sequences; the omicron samples tested 100 positive. None of the 27 organisms showed cross-reactivity with the Flash20 SARS-CoV-2 nucleic acid rapid detection system. Among all the 215 clinical samples, the Flash20 SARS-CoV-2 nucleic acid rapid detection system exhibits a high sensitivity of 99.24 (131/132) and 100 (83/83) specificity. Conclusion. The nucleic acid rapid detection system provides sensitive and accurate detection of SARS-CoV-2 free of RNA extraction. The high sensitivity and short time to results of approximately 35minutes may impact earlier infection control and disease management.

1 September 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YFYanyan Fan
Yanyan Fan
RSRongrong Song
Rongrong Song
JFJingyi Feng
Jingyi Feng
JZJiankang Zhao
Jiankang Zhao
Background: The slow-growing, fastidious nature of Nocardia species makes rapid molecular tools essential for diagnosis. Although the GeneXpert MTB/RIF assay targets Mycobacterium tuberculosis (MTB), the cross-reactivity of its Probe C with Nocardia has not previously been characterized. Methods: We retrospectively analyzed 14,141 non-duplicate clinical samples from February 2020 to June 2023. Probe C reactivity was first assessed against Nocardia culture results. To investigate the molecular basis, we subsequently compared the rpoB target region of Probe C with the genomes of 1082 Nocardia strains from the NCBI database. Results: Probe C showed species-specific reactivity, failing to detect many clinically prevalent species. Among culture-positive Nocardia isolates, Probe C detected 10 of 17 N. cyriacigeorgica (Ct range: 32.8– 39.2), 1 of 2 N. asiatica (Ct: 39), and 2 of 8 N. abscessus (Ct range: 30.5– 38.7). Notably, the most frequently isolated species, N. farcinica (59 isolates), showed no Probe C reactivity. The overall sensitivity of Probe C among all culture-confirmed nocardiosis cases was only 13.4% (13/97); even among the subset of cross-reacting species, it reached only 48.1% (13/27), highlighting its inadequacy as a standalone diagnostic test. In the full MTB-negative cohort, the Probe C-positive rate was just 0.27% (38/14,141), with 25 of those 38 signals lacking culture confirmation. Genome alignment confirmed 100% identity between the rpoB sequences of reactive Nocardia strains and the Probe C target region. Conclusion: Probe C is the first MTB-targeted tool demonstrated to cross-react with Nocardia via rpoB homology, with genomic evidence ruling out other genetic sources. However, given the low overall sensitivity of Probe C among all culture-confirmed nocardiosis cases, the restricted species spectrum, and the lack of molecular confirmation for most positive signals at high Ct values, an isolated Probe C-positive result in an MTB-negative sample should be regarded as a suggestive, non-diagnostic ancillary hint that warrants Nocardia-specific confirmatory testing rather than as a diagnostic finding.